Cargando…

Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1

Detalles Bibliográficos
Autores principales:	Makino, Yuki, Kamiyama, Yuki, Brown, J. B., Tanaka, Toshiya, Murakami, Ryusuke, Teramoto, Yuki, Goto, Takayuki, Akamatsu, Shusuke, Terada, Naoki, Inoue, Takahiro, Kodama, Tatsuhiko, Ogawa, Osamu, Kobayashi, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296574/ https://www.ncbi.nlm.nih.gov/pubmed/35854103 http://dx.doi.org/10.1038/s42003-022-03707-z

Ejemplares similares

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
por: Sumiyoshi, Takayuki, et al.
Publicado: (2019)

Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models
por: Nagai, Takahiro, et al.
Publicado: (2022)

Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer
por: Miyazaki, Yu, et al.
Publicado: (2019)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
por: Kita, Yuki, et al.
Publicado: (2019)

Pharmacological profiles of opioid ligands at Kappa opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2006)

Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer
por: Teramoto, Yuki, et al.
Publicado: (2021)

Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression
por: Jin, Renjie, et al.
Publicado: (2014)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Structure of the human kappa opioid receptor in complex with JDTic
por: Wu, Huixian, et al.
Publicado: (2012)

Identification of novel ligands interacting with kappa opioid receptors
por: Spetea, Mariana, et al.
Publicado: (2011)

Major Depressive Disorder and Kappa Opioid Receptor Antagonists
por: Li, Wei, et al.
Publicado: (2016)

The Kappa Opioid Receptor: From Addiction to Depression, and Back
por: Lalanne, Laurence, et al.
Publicado: (2014)

Kappa Opioid Receptor on Pulmonary Macrophages and Immune Function
por: Zeng, Si, et al.
Publicado: (2020)

Nanobody-enabled monitoring of kappa opioid receptor states
por: Che, Tao, et al.
Publicado: (2020)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
por: Sturaro, Chiara, et al.
Publicado: (2022)

Molecular mechanism of biased signaling at the kappa opioid receptor
por: El Daibani, Amal, et al.
Publicado: (2023)

GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer
por: Elahi Najafi, Mohammad Amin, et al.
Publicado: (2023)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system
por: Sirohi, Sunil, et al.
Publicado: (2012)

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
por: Greedy, Benjamin M., et al.
Publicado: (2013)

Differential Stability of the Crystallographic Interfaces of Mu- and Kappa-Opioid Receptors
por: Johnston, Jennifer M., et al.
Publicado: (2014)

Does the kappa opioid receptor system contribute to pain aversion?
por: Cahill, Catherine M., et al.
Publicado: (2014)

Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats
por: Page, Sarah, et al.
Publicado: (2019)

Signaling underlying kappa opioid receptor-mediated behaviors in rodents
por: Liu-Chen, Lee-Yuan, et al.
Publicado: (2022)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer
por: Jiang, Guiyang, et al.
Publicado: (2021)

Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits
por: Kim, Brian S., et al.
Publicado: (2022)

The Roles of Extracellular Vesicles in the Progression of Renal Cell Carcinoma and Their Potential for Future Clinical Application
por: Takeda, Masashi, et al.
Publicado: (2023)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation
por: Shokirova, Hurramhon, et al.
Publicado: (2021)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction
por: Chartoff, Elena H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f5sstvbad5dq2biobp4netbq72